Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Total Liabilities (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Total Liabilities for 13 consecutive years, with $214.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Total Liabilities rose 7.28% to $214.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $214.6 million, a 7.28% increase, with the full-year FY2025 number at $214.6 million, up 7.28% from a year prior.
  • Total Liabilities was $214.6 million for Q4 2025 at Iovance Biotherapeutics, up from $202.7 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $214.6 million in Q4 2025 to a low of -$773.5 million in Q3 2024.
  • A 3-year average of $32.0 million and a median of $192.8 million in 2023 define the central range for Total Liabilities.
  • Peak YoY movement for Total Liabilities: plummeted 533.78% in 2024, then surged 127.19% in 2025.
  • Iovance Biotherapeutics' Total Liabilities stood at $195.7 million in 2023, then grew by 2.19% to $200.0 million in 2024, then rose by 7.28% to $214.6 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Total Liabilities are $214.6 million (Q4 2025), $202.7 million (Q3 2025), and $208.9 million (Q2 2025).